Director Howard G. Welgus of Arcutis Biotherapeutics, Inc. filed a Form 4 on November 18, 2026, disclosing option exercises and a sale of common stock executed on November 16, 2026, under a 10b5-1 trading plan.
Key Highlights
- Reporting person: Howard G. Welgus, identified as a Director of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT).
- Option exercises: Welgus exercised three fully vested stock options on November 16, 2026, acquiring a total of 4,094 shares of common stock at exercise prices of $6.5223, $7.51, and $8.63 per share, respectively.
- Sale: 4,728 shares of common stock were disposed of on November 16, 2026, at a price of $28.16 per share.
- Remaining direct ownership: Following the reported transactions, Welgus directly owned 34,573 shares of common stock.
- 10b5-1 plan: According to the filing, all transactions were effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027.
- Remaining derivative securities: After the exercises, Welgus retained options to purchase 4,930, 6,108, and 13,524 shares under three separate stock option grants, all held directly.
Welgus Option Exercises and Share Sale at Arcutis Biotherapeutics on November 16, 2026
According to the Form 4 filed with the SEC on November 18, 2026, Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc., reported three option exercise transactions and one open-market sale, all occurring on November 16, 2026. The filing indicates each transaction was made under a Rule 10b5-1(c) trading plan that Welgus adopted on March 13, 2026, with a stated plan end date of June 15, 2027.
The three option exercises, each coded "M" in the filing, involved stock options with exercise prices of $6.5223 (822 shares acquired), $7.51 (1,018 shares acquired), and $8.63 (2,254 shares acquired). The filing notes that all three options were fully vested at the time of exercise. The price of each derivative security at exercise is listed as $0. Following these exercises and before the reported sale, beneficial ownership increased incrementally with each transaction, reaching 39,301 shares directly held.
The filing then reports a sale coded "S" of 4,728 shares at $28.16 per share, leaving Welgus with 34,573 shares of common stock held directly. On the derivative side, the three corresponding option positions were reduced to 4,930, 6,108, and 13,524 shares remaining, respectively, all held directly. The Form 4 was signed by Latha Vairavan as Attorney-in-Fact for Howard G. Welgus on November 18, 2026.
What Was Disclosed
Howard G. Welgus, a director at Arcutis Biotherapeutics, disclosed the exercise of three fully vested stock options totaling 4,094 shares and the sale of 4,728 shares at $28.16 on November 16, 2026, all under a pre-established 10b5-1 trading plan. Direct ownership following the transactions stood at 34,573 shares.




Please wait processing your request...